Cited 54 times in
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이용호 | - |
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 이오현 | - |
dc.contributor.author | 오재원 | - |
dc.contributor.author | 전옥희 | - |
dc.contributor.author | 홍성진 | - |
dc.contributor.author | 박세일 | - |
dc.contributor.author | 안철민 | - |
dc.date.accessioned | 2020-09-28T11:34:20Z | - |
dc.date.available | 2020-09-28T11:34:20Z | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 1738-5520 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/179231 | - |
dc.description.abstract | Background and objectives: We sought to investigate an anti-atherosclerotic and anti-inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model. Methods: Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet for 7 weeks followed by normal diet for 2 weeks. After balloon catheter injury, the rabbits were administered with the Dapagliflozin (1mg/kg/day) or control-medium for 8 weeks (n=13 for each group). All lesions were assessed with angiography, optical coherence tomography (OCT), and histological assessment. Results: Atheroma burden (38.51±3.16% vs. 21.91±1.22%, p<0.01) and lipid accumulation (18.90±3.63% vs. 10.20±2.03%, p=0.047) was significantly decreased by SGLT-2 inhibitor treatment. The SGLT-2 inhibitor group showed lower macrophage infiltration (20.23±1.89% vs. 12.72±1.95%, p=0.01) as well as tumor necrosis factor (TNF)-α expression (31.17±4.40% vs. 19.47±2.10%, p=0.025). Relative area of inducible nitric oxide synthase⁺ macrophages was tended to be lower in the SGLT-2 inhibitor-treated group (1.00±0.16% vs. 0.71±0.10%, p=0.13), while relative proportion of Arg1⁺ macrophage was markedly increased (1.00±0.27% vs. 2.43±0.64%, p=0.04). As a result, progression of atherosclerosis was markedly attenuated in SGLT-2 inhibitor treated group (OCT area stenosis, 32.13±1.20% vs. 22.77±0.88%, p<0.01). Mechanistically, SGLT-2 treatment mitigated the inflammatory responses in macrophage. Especially, Toll-like receptor 4/nuclear factor-kappa B signaling pathway, and their downstream effectors such as interleukin-6 and TNF-α were markedly suppressed by SGLT-2 inhibitor treatment. Conclusions: These results together suggest that SGLT-2 inhibitor exerts an anti-atherosclerotic effect through favorable modulation of inflammatory response as well as macrophage characteristics in non-diabetic situation. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English, Korean | - |
dc.publisher | Korean Society of Circulation | - |
dc.relation.isPartOf | KOREAN CIRCULATION JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seul Gee Lee | - |
dc.contributor.googleauthor | Seung Jun Lee | - |
dc.contributor.googleauthor | Jung Jae Lee | - |
dc.contributor.googleauthor | Jung Sun Kim | - |
dc.contributor.googleauthor | Oh Hyun Lee | - |
dc.contributor.googleauthor | Choong Ki Kim | - |
dc.contributor.googleauthor | Darae Kim | - |
dc.contributor.googleauthor | Yong Ho Lee | - |
dc.contributor.googleauthor | Jaewon Oh | - |
dc.contributor.googleauthor | Seil Park | - |
dc.contributor.googleauthor | Ok Hee Jeon | - |
dc.contributor.googleauthor | Sung Jin Hong | - |
dc.contributor.googleauthor | Chul Min Ahn | - |
dc.contributor.googleauthor | Byeong Keuk Kim | - |
dc.contributor.googleauthor | Young Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.identifier.doi | 10.4070/kcj.2019.0296 | - |
dc.contributor.localId | A02989 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A05648 | - |
dc.relation.journalcode | J01952 | - |
dc.identifier.eissn | 1738-5555 | - |
dc.identifier.pmid | 32153145 | - |
dc.subject.keyword | Atherosclerosis | - |
dc.subject.keyword | Macrophages | - |
dc.subject.keyword | Sodium-glucose transporter 2 inhibitors | - |
dc.subject.keyword | Sodium-glucose transporter-2 | - |
dc.contributor.alternativeName | Lee, Yong Ho | - |
dc.contributor.affiliatedAuthor | 이용호 | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.citation.volume | 50 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 443 | - |
dc.citation.endPage | 457 | - |
dc.identifier.bibliographicCitation | KOREAN CIRCULATION JOURNAL, Vol.50(5) : 443-457, 2020-05 | - |
dc.identifier.rimsid | 67439 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.